HighTower Advisors LLC increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.2% in the second quarter, HoldingsChannel.com reports. The firm owned 5,976 shares of the company’s stock after buying an additional 131 shares during the period. HighTower Advisors LLC’s holdings in Henry Schein were worth $441,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. JLB & Associates Inc. boosted its position in shares of Henry Schein by 1.6% during the 2nd quarter. JLB & Associates Inc. now owns 88,584 shares of the company’s stock worth $6,572,000 after purchasing an additional 1,401 shares during the period. Stephens Investment Management Group LLC boosted its position in Henry Schein by 8.5% in the 1st quarter. Stephens Investment Management Group LLC now owns 76,827 shares of the company’s stock valued at $5,320,000 after buying an additional 6,011 shares during the period. Voloridge Investment Management LLC boosted its position in Henry Schein by 21.1% in the 1st quarter. Voloridge Investment Management LLC now owns 94,449 shares of the company’s stock valued at $6,540,000 after buying an additional 16,473 shares during the period. Bessemer Group Inc. boosted its position in Henry Schein by 1.6% in the 1st quarter. Bessemer Group Inc. now owns 9,860 shares of the company’s stock valued at $683,000 after buying an additional 151 shares during the period. Finally, IFM Investors Pty Ltd boosted its position in Henry Schein by 30.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 19,269 shares of the company’s stock valued at $1,430,000 after buying an additional 4,490 shares during the period. 93.16% of the stock is owned by hedge funds and other institutional investors.
Shares of HSIC opened at $77.60 on Friday. Henry Schein, Inc. has a twelve month low of $56.31 and a twelve month high of $83.45. The firm’s fifty day simple moving average is $77.00 and its 200-day simple moving average is $74.91. The firm has a market capitalization of $10.84 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.32 and a beta of 0.88. The company has a current ratio of 1.79, a quick ratio of 0.98 and a debt-to-equity ratio of 0.18.
Several equities analysts have commented on HSIC shares. Barrington Research raised their price target on shares of Henry Schein from $91.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, August 4th. Piper Sandler raised their price objective on shares of Henry Schein from $89.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, August 3rd. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $89.25.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
See Also: What’s a Black Swan?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.